The European Medicines Agency (EMA) recommends extension of indications for daratumumabAccess, MyelomaOctober 21, 2019
European Commission approves elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory myelomaAccess, MyelomaAugust 28, 2019
Janssen seeks European marketing authorisation for subcutaneous (under the skin) daratumumab (Darzalex®)Access, MyelomaJuly 19, 2019
HARMONY reaches milestone capturing data from 45,000 patients with blood cancersMPE, MyelomaJune 25, 2019
ASCO 2019 – Lenalidomide reduces risk that smoldering myeloma will progress to myeloma in high risk patientsConferences, MyelomaMay 31, 2019
Lenalidomide and pomalidomide based triplet combination regimens for myeloma patients receives approval from the European CommissionAccess, MyelomaMay 23, 2019
Results of MPE members participation in EMA survey on bortezomibMPE, Myeloma, Patient evidenceMay 3, 2019
MPE will hold a webinar on ASH 2018 highlights in myeloma and AL amyloidosisAL amyloidosis, Conferences, MPE, MyelomaJanuary 16, 2019
